{"id":16343,"date":"2026-06-18T10:38:30","date_gmt":"2026-06-18T05:08:30","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=16343"},"modified":"2026-06-18T10:38:40","modified_gmt":"2026-06-18T05:08:40","slug":"avience-biomedicals-ipo-opens-key-details-investors-shouldnt-miss","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/avience-biomedicals-ipo-opens-key-details-investors-shouldnt-miss\/","title":{"rendered":"Avience Biomedicals IPO Opens: Key Details Investors Shouldn\u2019t Miss"},"content":{"rendered":"

[vc_section el_id=”blog-inner-layout”][vc_row overlay_dotted=””][vc_column el_class=”blog_primary”][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n

India’s healthcare and diagnostics industry continues to witness rapid growth, driven by rising healthcare awareness, increasing incidence of infectious and lifestyle diseases, expanding diagnostic infrastructure, and greater adoption of advanced medical technologies. The demand for molecular diagnostics, rapid testing solutions, and laboratory automation has increased significantly as hospitals, pathology laboratories, and research institutions continue to modernise their diagnostic capabilities. This has created strong growth opportunities for companies operating in the in vitro diagnostics (IVD) and medical devices industry.<\/p>\n

Against this backdrop, Avience Biomedicals Limited is set to open its IPO on June 18, 2026. The company specialises in molecular diagnostic solutions and medical devices, serving pathology laboratories, hospitals, research centres, and government institutions. Here is a detailed insight into Avience Biomedicals Limited, its IPO, and the industry outlook.<\/p>\n

<\/span>About Avience Biomedicals Ltd.<\/span><\/h2>\n

Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company engaged in the manufacturing, supply, and export of molecular diagnostic solutions with a focus on biotechnology, genomics, and the in vitro diagnostics (IVD) industry.<\/p>\n

The company has expanded its product portfolio from rapid diagnostic test kits to a comprehensive range of medical devices, including serology products, molecular diagnostics, biochemistry analysers, haematology analysers, and laboratory equipment. It primarily caters to B2B and B2G customers across India and overseas.<\/p>\n

Apart from manufacturing, the company also operates as a distributor and trader of medical equipment.<\/p>\n

Its manufacturing facility is located in Noida, Uttar Pradesh.<\/p>\n

The company’s product portfolio includes:<\/p>\n

\u2022 Rapid Test Kits
\u2022 Biochemistry Analysers and Reagents
\u2022 Molecular Diagnostic Kits
\u2022 Haematology Analysers
\u2022 Medical Devices such as Oxygen Concentrators and Viral Transport Media (VTM)<\/p>\n

As of January 31, 2026, the company had 75 permanent employees and 33 contractual employees.<\/p>\n

<\/span>Avience Biomedicals Ltd. IPO Details<\/span><\/h2>\n

With the IPO launch, Avience Biomedicals Ltd. intends to utilise the net proceeds towards expansion of its manufacturing capabilities and business operations.<\/p>\n

The company plans to utilise approximately \u20b915.96 crore towards part financing the capital expenditure for setting up a new manufacturing unit at the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh. In addition, \u20b98.25 crore will be utilised towards meeting working capital requirements. The remaining amount will be used for general corporate purposes.<\/p>\n

<\/span>Important IPO Timeline<\/span><\/h2>\n
\n
\n\n\n\n\n\n\n\n\n\n\n
Particulars<\/th>\nDetails<\/th>\n<\/tr>\n<\/thead>\n
IPO Open Date<\/td>\nJune 18, 2026<\/td>\n<\/tr>\n
IPO Close Date<\/td>\nJune 22, 2026<\/td>\n<\/tr>\n
Allotment Date (Tentative)<\/td>\nJune 23, 2026<\/td>\n<\/tr>\n
Initiation of Refunds<\/td>\nJune 24, 2026<\/td>\n<\/tr>\n
Credit of Shares to Demat<\/td>\nJune 24, 2026<\/td>\n<\/tr>\n
Listing Date (Tentative)<\/td>\nJune 25, 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n

<\/span>Key IPO Details<\/span><\/h2>\n

Here is the table on the Avience Biomedicals IPO Review:<\/p>\n

\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Particulars<\/th>\nDetails<\/th>\n<\/tr>\n<\/thead>\n
Face Value<\/td>\n\u20b910 per share<\/td>\n<\/tr>\n
Price Band<\/td>\n\u20b9196 to \u20b9208 per share<\/td>\n<\/tr>\n
Lot Size<\/td>\n600 Shares<\/td>\n<\/tr>\n
Total Issue Size<\/td>\n14,53,800 shares (aggregating up to \u20b930.24 Cr)<\/td>\n<\/tr>\n
Fresh Issue<\/td>\n14,53,800 shares (aggregating up to \u20b930.24 Cr)<\/td>\n<\/tr>\n
Fresh Issue (Ex Market Maker)<\/td>\n13,71,600 shares (aggregating up to \u20b928.53 Cr)<\/td>\n<\/tr>\n
Net Offered to Public<\/td>\n13,71,600 shares (aggregating up to \u20b928.53 Cr)<\/td>\n<\/tr>\n
Reserved for Market Maker<\/td>\n82,200 shares (aggregating up to \u20b91.71 Cr)<\/td>\n<\/tr>\n
Issue Type<\/td>\nBookbuilding IPO<\/td>\n<\/tr>\n
Sale Type<\/td>\nFresh Capital Only<\/td>\n<\/tr>\n
Listing At<\/td>\nNSE SME<\/td>\n<\/tr>\n
Market Capitalisation (Pre IPO)<\/td>\n\u20b9114.09 Cr<\/td>\n<\/tr>\n
Shareholding Pre Issue<\/td>\n40,31,256 shares<\/td>\n<\/tr>\n
Shareholding Post Issue<\/td>\n54,85,056 shares<\/td>\n<\/tr>\n
Book Running Lead Manager<\/td>\nFintellectual Corporate Advisors Pvt. Ltd.<\/td>\n<\/tr>\n
Registrar<\/td>\nSkyline Financial Services Pvt. Ltd.<\/td>\n<\/tr>\n
Market Maker<\/td>\nAsnani Stock Broker Pvt. Ltd.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n

<\/span>Lot Size of Avience Biomedicals IPO<\/span><\/h2>\n

Here is the table of lot sizes for each category of investors:<\/p>\n

\n
\n\n\n\n\n\n\n\n\n\n
Application<\/th>\nLots<\/th>\nShares<\/th>\nAmount<\/th>\n<\/tr>\n<\/thead>\n
Individual Investors (Min)<\/td>\n2<\/td>\n1,200<\/td>\n\u20b92,49,600<\/td>\n<\/tr>\n
Individual Investors (Max)<\/td>\n2<\/td>\n1,200<\/td>\n\u20b92,49,600<\/td>\n<\/tr>\n
S HNI (Min)<\/td>\n3<\/td>\n1,800<\/td>\n\u20b93,74,400<\/td>\n<\/tr>\n
S HNI (Max)<\/td>\n8<\/td>\n4,800<\/td>\n\u20b99,98,400<\/td>\n<\/tr>\n
B HNI (Min)<\/td>\n9<\/td>\n5,400<\/td>\n\u20b911,23,200<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n

<\/span>Avience Biomedicals Ltd. Financials<\/span><\/h2>\n

The Avience Biomedicals IPO has a pre IPO market capitalisation of \u20b9114.09 crore. As of January 31, 2026, its key performance indicators showcase a Return on Equity (ROE) of 22.38% and a Return on Capital Employed (ROCE) of 16.99%. The Return on Net Worth (RoNW) stood at 22.38%, while the company reported an EBITDA margin of 24.70%. Its debt to equity ratio stood at 0.94, reflecting a moderate leverage position.<\/p>\n

The company has demonstrated steady financial performance over recent years. Its diversified product portfolio and growing presence in the diagnostics and medical devices industry have supported healthy profitability and business growth.<\/p>\n

Other financial details of the company include the following:<\/p>\n

<\/span>Key Company Financials<\/span><\/h2>\n
\n
\n\n\n\n\n\n\n\n\n\n\n\n
Period Ended<\/th>\n31 Jan 2026 (Crores)<\/th>\n31 Mar 2025 (Crores)<\/th>\n31 Mar 2024 (Crores)<\/th>\n<\/tr>\n<\/thead>\n
Assets<\/td>\n\u20b966.07<\/td>\n\u20b956.52<\/td>\n\u20b934.65<\/td>\n<\/tr>\n
Total Income<\/td>\n\u20b941.94<\/td>\n\u20b945.97<\/td>\n\u20b924.37<\/td>\n<\/tr>\n
Profit After Tax<\/td>\n\u20b95.74<\/td>\n\u20b97.23<\/td>\n\u20b92.14<\/td>\n<\/tr>\n
EBITDA<\/td>\n\u20b910.34<\/td>\n\u20b911.41<\/td>\n\u20b94.08<\/td>\n<\/tr>\n
Net Worth<\/td>\n\u20b928.52<\/td>\n\u20b922.78<\/td>\n\u20b96.21<\/td>\n<\/tr>\n
Reserves and Surplus<\/td>\n\u20b924.49<\/td>\n\u20b918.75<\/td>\n\u20b92.93<\/td>\n<\/tr>\n
Total Borrowing<\/td>\n\u20b926.73<\/td>\n\u20b922.16<\/td>\n\u20b915.13<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n

<\/span>Avience Biomedicals Ltd.: Industry Outlook<\/span><\/h2>\n

\u2022 India’s diagnostics market continues to expand due to increasing healthcare expenditure, rising disease awareness, and greater adoption of preventive healthcare.<\/p>\n

\u2022 Molecular diagnostics and genomics are becoming increasingly important for the early detection and management of infectious diseases, genetic disorders, and chronic illnesses.<\/p>\n

\u2022 Growing investments in healthcare infrastructure, pathology laboratories, and research institutions are supporting demand for advanced diagnostic equipment and medical devices.<\/p>\n

\u2022 Government initiatives aimed at strengthening domestic medical device manufacturing are creating opportunities for companies operating in this sector.<\/p>\n

\u2022 Increasing demand for automated laboratory equipment, rapid test kits, and molecular diagnostic solutions is expected to drive long term industry growth.<\/p>\n

\u2022 Avience Biomedicals’ diversified product portfolio, manufacturing capabilities, and expanding distribution network position the company to benefit from these industry trends.<\/p>\n

<\/span>Conclusion<\/span><\/h2>\n

Avience Biomedicals Ltd. presents an interesting investment opportunity because of its presence in the rapidly growing molecular diagnostics and medical devices industry. The company offers a diversified portfolio of diagnostic products, laboratory equipment, and healthcare solutions catering to hospitals, pathology laboratories, research centres, and government institutions.<\/p>\n

The company has established manufacturing capabilities, an expanding product portfolio, and a growing distribution network across domestic and international markets. Furthermore, the proposed utilisation of IPO proceeds towards setting up a new manufacturing facility and strengthening working capital may support future business expansion.<\/p>\n

However, potential investors should consider factors such as competition within the diagnostics and medical devices industry, regulatory compliance requirements, technological advancements, and dependence on healthcare spending before making an investment decision. As with any SME IPO, investors should carefully evaluate their risk appetite and investment horizon before investing.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text css=””][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=”share_rating”][vc_column_inner width=”1\/2″][vc_column_text css=””]<\/p>\n

Rate this article<\/h6>\n